Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company's lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. Contineum Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California. Show more
Location: 3565 General Atomics Court, San Diego, CA, 92121, United States | Website: https://www.contineum-tx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
96.5M
52 Wk Range
$3.35 - $21.92
Previous Close
$3.73
Open
$3.85
Volume
118,856
Day Range
$3.77 - $3.92
Enterprise Value
-82.0M
Cash
190.7M
Avg Qtr Burn
-9.821M
Insider Ownership
1.82%
Institutional Own.
79.99%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PIPE-307 Details Relapsing-remitting multiple sclerosis (RRMS) | Phase 2 Data readout | |
PIPE-791 Details Osteoarthritis (OA) and low back pain (LBP) | Phase 1b Data readout | |
PIPE-791 Details Neuroscience, Inflammation and Immunology (NI&I) Indications | Phase 1b Data readout |